Lantheus Holdings, Inc. $LNTH Shares Purchased by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 46.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,024 shares of the medical equipment provider’s stock after buying an additional 9,781 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Lantheus were worth $1,591,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new position in shares of Lantheus during the third quarter worth approximately $65,654,000. Polaris Capital Management LLC purchased a new stake in Lantheus in the 3rd quarter valued at $32,687,000. Norges Bank acquired a new stake in Lantheus during the 2nd quarter worth $32,631,000. Galvin Gaustad & Stein LLC purchased a new position in Lantheus during the 2nd quarter worth $11,899,000. Finally, Boston Partners increased its stake in Lantheus by 30.5% in the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after purchasing an additional 134,781 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on LNTH shares. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Truist Financial increased their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Finally, Mizuho upped their price target on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Trading Up 0.5%

Shares of LNTH opened at $67.51 on Friday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $4.48 billion, a P/E ratio of 28.37 and a beta of -0.11. The firm’s 50-day moving average is $63.52 and its two-hundred day moving average is $60.57.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. The company had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the firm earned $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.